Skip to main content

Table 2 The descriptive data, clinical and echocardiographic parameters comparison between Strauss and non- Strauss group

From: Role of Strauss ECG criteria as predictor of response in patients undergoing cardiac resynchronization therapy

 

Non-Strauss

Strauss

Test value

P-value

Sig.

No. = 37

No. = 30

Age

     

Mean ± SD

62.97 ± 5.69

62.07 ± 6.08

0.629•

0.532

NS

Range

52–74

52–73

   

Gender

     

Male

24 (64.9%)

15 (50.0%)

1.505*

0.220

NS

Female

13 (35.1%)

15 (50.0%)

   

BMI

     

Mean ± SD

30.00 ± 3.25

32.07 ± 5.60

− 1.890•

0.063

NS

Range

24–37

24–46

   

Diabetes

     

Yes

22 (59.5%)

18 (60.0%)

0.002*

0.964

NS

HTN

     

Yes

18 (48.6%)

26 (86.7%)

10.622*

0.001

HS

CKD

     

eGFR > 60

33 (89.2%)

24 (80%)

9.395*

0.009

HS

eGFR30-60

4 (10.8%)

6 (20.0%)

   

Cardiomyopathy

     

DCM

21 (56.8%)

13 (43.3%)

1.194*

0.274

NS

ICM

16 (43.2%)

17 (56.7%)

   

ACEI

     

Yes

27 (73.0%)

24 (80.0%)

0.450*

0.502

NS

ARNI

     

Yes

4 (10.8%)

3 (10.0%)

0.012*

0.914

NS

BB

     

Yes

37 (100.0%)

30 (100.0%)

NA

NA

NS

Diuretics

     

Yes

37 (100.0%)

27 (90.0%)

3.873*

0.049

S

MRAs

     

Yes

23 (62.2%)

21 (70.0%)

0.451*

0.502

NS

SGLT2 inh

     

Yes

4 (10.8%)

4 (13.3%)

0.100*

0.752

NS

QRS duration (msec)

     

Mean ± SD

134.32 ± 7.65

166.33 ± 22.05

− 8.251•

 < 0.001

HS

Range

130–160

140–200

   

NYHA improvement

     

No

10 (27.8%)

6 (20.0%)

9.562*

0.023

S

One-class

23 (63.9%)

12 (40.0%)

   

Two-class

3 (8.3%)

11 (36.7%)

   

Three-class

0 (0.0%)

1 (3.3%)

   

ESV reduction

     

Mean ± SD

15.63 ± 2.34

17.92 ± 4.47

3.352•

0.023

S

Range

5–18

5–27

   

EF improvement by Simpson

     

Mean ± SD

5.81 ± 0.85

9.42 ± 3.05

5.801•

 < 0.001

HS

Range

5–8

6–15

   

GLS improvement

     

Median (IQR)

− 3 (− 4 to − 3)

− 6 (− 7 to − 4)

4.732

 < 0.001

HS

Range

− 6–0

− 11 to − 2

   

GCS improvement

     

Median (IQR)

− 3 (− 4 to − 2)

− 7 (− 8 to − 5)

4.919

 < 0.001

HS

Range

− 7–0

− 10 to − 2

   

6-month Hosp

     

Yes

13 (35.1%)

12 (40%)

0.676*

0.879

NS

Mortality

     

Yes

1 (2.7%)

0(0%)

0.823*

0.364

NS

  1. Angiotensin converting enzyme inhibitor, angiotensin receptor neutrilypsin inhibitor, beta-blockers, body mass index, chronic kidney disease, dilated cardiomyopathy, hypertension, ischemic cardiomyopathy, mineralocorticoids receptor antagonists, standard deviation, end systolic volume, ejection fraction, global longitudinal strain, global circumferential strain, New York Heart Association, right ventricle systolic pressure, standard deviation, tricuspid regurgitation. *: Chi-square test; •: Independent t-test; ≠: Mann-Whitney test